hI-con1

Drug Profile

hI-con1

Alternative Names: hI-con1; hIcon1; ICON-1

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Yale University
  • Developer Iconic Therapeutics; Yale University
  • Class Antineoplastics; Eye disorder therapies; Immunoconjugates; Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Natural killer cell stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Uveal melanoma
  • Research Solid tumours
  • No development reported Cancer

Most Recent Events

  • 01 Sep 2016 Iconic Therapeutics completes the phase II EMERGE trial for Wet age-related macular degeneration (In adults, In the elderly) in USA (NCT02358889)
  • 09 Aug 2016 Early research in Solid tumours in USA (Parenteral)
  • 09 Aug 2016 Iconic Therapeutics completes enrolment in the phase II EMERGE trial for Wet age-related macular degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top